At present, MBL is conducting collaborative research to generate neutralizing monoclonal antibodies against swine-origin influenza A (H1N1). MBL is preparing to collaborate with more institutions regarding other infectious viruses.
The fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza viruses were generated by the utilization of SPYMEG. The antibodies, originated from the blood of a convalescent volunteer recovering from influenza infection or vaccination, are expected to be effective and very safe.
Additionally, the simple principle and wide range of applications of this method may lead to the generation of therapeutic and prophylactic drugs to various infections such as avian influenza A (H5N1).
MBL was first established as a Japanese antibody manufacturer in 1969. Since then, the company has been involved in the research, development, manufacture and sale of diagnostic and research reagents.
In the research reagent sector, MBL has been engaged in the worldwide sales of more than 8,000 antibodies that are developed in-house or marketed by foreign and domestic alliance partners. MBL also provides the contract manufacturing of custom-made monoclonal and polyclonal antibodies. MBL has also extended its offering to provide identification kits for mRNA and contract analysis of carbohydrate structure.
In the diagnostic reagent sector, MBL has developed in vitro diagnostic reagents for autoimmune diseases, cancers and aberrant metabolite disorders. As a leader in autoimmune disease diagnostics, MBL's diagnostic products have aided detection of diseases, especially those with poor therapeutic options. MBL also provides an advanced cytopreparation system for the sampling and diagnosis of cervical cancer.
MBL is proud to be an antibody manufacturer with commitment to
|SOURCE MBL International Corporation|
Copyright©2010 PR Newswire.
All rights reserved